Arvinas, INC 8-K filings

Arvinas has updated its guidance for vepdegestrant clinical trials, highlighted upcoming milestones, and provided a corporate update, including a change in the Chief Commercial Officer role.

Arvinas, Inc. has expanded its office and laboratory space in New Haven, Connecticut, by approximately 9,700 square feet through an amendment to its existing lease.

Arvinas has amended its leases for two facilities in New Haven, expanding one and extending both through 2029, with options for further renewal.

Arvinas and Pfizer reported encouraging preliminary results from a Phase 1b study of vepdegestrant combined with abemaciclib for advanced breast cancer, showing a tolerable safety profile and a 62.5% clinical benefit rate.

Arvinas and Pfizer have reprojected the primary completion date for their Phase 3 breast cancer trial, pushing top-line data release to the first quarter of 2025.

Arvinas announced its third quarter 2024 financial results, highlighting progress in clinical trials and a strong cash position, while remaining on track for key data readouts.

Arvinas, Inc. has terminated its lease for office space in New Haven, Connecticut, incurring a one-time termination fee of $41.5 million.

Arvinas reported its second quarter 2024 financial results, highlighted by a $150 million upfront payment from Novartis and progress in multiple clinical trials.

Arvinas, Inc. has appointed Andrew Saik as its new chief financial officer, treasurer, and principal financial officer, effective June 24, 2024.

Arvinas has amended its license agreement with Yale University, making a $14.95 million payment and agreeing to future milestone and royalty payments.

Arvinas, Inc. has appointed Ian Taylor, Ph.D. as President of R&D and Angela Cacace, Ph.D. as Chief Scientific Officer, effective June 15, 2024.

Arvinas, Inc. held its annual meeting of stockholders on May 29, 2024, where key proposals were voted on, including the election of directors and ratification of the company's accounting firm.

Arvinas, Inc. has received a $150 million upfront payment from Novartis after the expiration of the Hart-Scott-Rodino waiting period, marking a significant step in their licensing and asset purchase agreement.

Arvinas and Pfizer reported updated clinical trial data showing continued encouraging results for vepdegestrant in combination with palbociclib for advanced breast cancer patients.

Arvinas reported its Q1 2024 financial results, highlighted by a significant licensing agreement with Novartis and progress in its clinical programs.

Arvinas has entered into a strategic agreement with Novartis, granting them exclusive rights to develop and commercialize ARV-766, a prostate cancer treatment, for an upfront payment of $150 million and potential milestone payments of up to $1.01 billion.

Arvinas, Inc. has appointed Noah Berkowitz as its new chief medical officer, effective March 18, 2024, while Ron Peck, the previous CMO, will transition out of the company by mid-April 2024.

Arvinas announced its full year 2023 financial results, highlighted by progress in multiple clinical trials and the initiation of new Phase 3 studies for its lead drug candidates.

Arvinas, Inc. has announced the resignation of its CFO, Sean Cassidy, effective February 29, 2024, and the appointment of Randy Teel as interim CFO.